It’s a common perception that venture investors have turned their backs—or at least hidden their pocketbooks—from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn’t exactly true. Even as the pool of available capital shrinks and despite the gloomy exit environment, start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding.
One company that recently emerged from stealth mode: Anchor Therapeutics Inc., which aims to develop drug candidates that interfere...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
